Zacks Investment Research
23 Jun 2026, 15:50 UTC · 1h ago
ABBV Jumps on Deepening Immunology Portfolio With $10.9B APGE Buyout
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
23 Jun 2026, 15:50 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
AbbVie entered into a definitive agreement to acquire Apogee Therapeutics (APGE) for $135.11 per share, valuing the deal at approximately $10.9 billion. — A multi-billion dollar acquisition typically drives immediate price action for the target company and signals strategic expansion for the acquirer.
+0.60The acquisition centers on zumilokibart, a phase III-ready monoclonal antibody for atopic dermatitis designed to reduce injection frequency compared to existing biologics. — Adding a late-stage, competitive asset to the immunology franchise reduces pipeline risk and supports future revenue growth.
+0.40AbbVie expects the acquisition to be earnings accretive starting in 2032, but anticipates adjusted EPS dilution of 14 cents in 2026 and 46 cents in 2027. — Short-to-medium term earnings dilution can create headwinds for the stock price despite long-term strategic benefits.
-0.30Continue reading
6 related stories
Search tags
The transaction has been unanimously approved by both boards and is expected to close in the third quarter. — Clear timeline and board approval reduce the likelihood of regulatory or internal deal failure.
+0.10Which stocks this story touches
Shares reached a 52-week high after being acquired by AbbVie for $135.11 per share.
Shares rose over 6% following the strategic acquisition of Apogee Therapeutics to strengthen its immunology franchise.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
Zacks Investment Research
36m ago
